Levy Adam Scott — SEC Form 4 filings
SEC reporting owner CIK 1693134. 13 Form 4 filings on record with FilingPulse; latest filed 2026-02-20.
Transaction summary — filings shown
Covers all 13 filings on record, filed 2024-02-15 to 2026-02-20. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 23 legs across 10 filings — 365,319 shares, $9,162,018 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 12.
- Largest priced transaction: sale of 38,900 shares @ $45.93 ($1,786,588) in Mineralys Therapeutics, Inc., filed 2025-11-13.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Mineralys Therapeutics, Inc. (MLYS) | CFO and Secretary | 13 | — | 23 legs · 365,319 sh · $9,162,018 | 12 |
Form 4 filings — Levy Adam Scott
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-02-20 | 4 | Mineralys Therapeutics, Inc. (MLYS) | Grant/award (A): 39,900 @ $0 · Grant/award (A): 53,300 (derivative) @ $0 | EDGAR |
| 2026-01-13 | 4 | Mineralys Therapeutics, Inc. (MLYS) | Sale (S): 10,758 @ $32.14 | EDGAR |
| 2025-11-13 | 4 | Mineralys Therapeutics, Inc. (MLYS) | Option exercise (M): 20,547 @ $10.20 · Option exercise (M): 34,414 @ $16 · Option exercise (M): 44,079 @ $14.25 · Option exercise (M): 6,613 @ $15.44 · Sale (S): 1,015 @ $42 · Sale (S): 11,295 @ $41.87 · +11 more | EDGAR |
| 2025-10-15 | 4 | Mineralys Therapeutics, Inc. (MLYS) | Sale (S): 7,366 @ $41.90 · Sale (S): 3,392 @ $42.26 | EDGAR |
| 2025-07-30 | 4 | Mineralys Therapeutics, Inc. (MLYS) | Sale (S): 12,946 @ $14.04 · Sale (S): 807 @ $14.00 · Sale (S): 51,500 @ $14.70 · Sale (S): 8,425 @ $15.10 | EDGAR |
| 2025-07-15 | 4 | Mineralys Therapeutics, Inc. (MLYS) | Sale (S): 10,758 @ $14.45 | EDGAR |
| 2025-04-15 | 4 | Mineralys Therapeutics, Inc. (MLYS) | Sale (S): 10,757 @ $12.06 | EDGAR |
| 2025-02-24 | 4 | Mineralys Therapeutics, Inc. (MLYS) | Grant/award (A): 170,000 (derivative) @ $0 | EDGAR |
| 2025-01-15 | 4 | Mineralys Therapeutics, Inc. (MLYS) | Sale (S): 10,657 @ $9.09 · Sale (S): 100 @ $9.63 | EDGAR |
| 2024-10-15 | 4 | Mineralys Therapeutics, Inc. (MLYS) | Sale (S): 10,757 @ $13.57 | EDGAR |
| 2024-07-12 | 4 | Mineralys Therapeutics, Inc. (MLYS) | Sale (S): 10,757 @ $13.14 | EDGAR |
| 2024-06-13 | 4 | Mineralys Therapeutics, Inc. (MLYS) | Sale (S): 96,815 @ $12.94 | EDGAR |
| 2024-02-15 | 4 | Mineralys Therapeutics, Inc. (MLYS) | Grant/award (A): 200,000 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1693134 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →